Damit ihr Bescheid wißt: Boiron ist in der Todesspirale.
http://www.lepoint.fr/economie/boiron-le-dg-christian-boiron-sur-le-depart-en-pleine-fronde-contre-l-homeopathie-05-09-2018-2248927_28.php[*quote*]
Actualité Économie
Boiron: le DG Christian Boiron sur le départ, en pleine fronde contre l'homéopathie
AFP
Publié le 05/09/2018 à 19:51 | AFP
[...]
[*/quote*]
Google Übersetzer
[*quote*]
4109/5000
News Economy
Boiron: DG Christian Boiron on the start, in full swing against homeopathy
AFP
Posted on 05/09/2018 at 19:51 | AFP
Boiron: DG Christian Boiron on the start, in full swing against homeopathy © AFP / Archives / FRED TANNEAU
Christian Boiron, emblematic general director of the French giant of homeopathy Boiron, announced Wednesday his departure on January 1, 2019, while the family group is in trouble, against a backdrop of the debate on homeopathy in France.
Valérie Poinsot, 49 years old and managing director for seven years, "was appointed to succeed him," said the group in a terse statement, without revealing the reasons for the departure of the captain.
This is the first time that the Lyon group, founded in the late 1960s by Christian Boiron's father and uncle, will be run by a non-family member.
Today, 71 years old, Christian Boiron was CEO of the group since July 2011, his brother Thierry being the president.
But the two brothers already shared the power within the group before, dividing them, over the years, presidency and general direction.
Christian Boiron joined the company in 1970 when he had just graduated as a pharmacist. At the time, he did not think "to fizzle out," he said in a personal book published in 2016, "Research in homeopathy."
"My passion was social, and then, little by little, I discovered that management and medicine were close relatives (...), in both cases I felt a strong need for philosophical and ethical reflection. ", again wrote the one who was often cited as a" social boss "and a forerunner of" well-being "in business.
Just over two years ago, he responded with a sharp "no" when AFP asked him if he expected to hang up soon.
Benefits at half-mast
But if the time to leave is a surprise, the appointment of Valérie Poinsot in his place is not one: in recent years the general manager had made her runner up.
Before joining Boiron in 2000 and gradually climbing up the ladder, Ms. Poinsot graduated from the Publicis advertising agency in 1991 with a degree in marketing and management. It was later passed by the laboratories Fournier, then Urgo.
The departure of Mr. Boiron occurs as the group goes through a period of turbulence, against a backdrop of declining results and revival of debate in France on the effectiveness of homeopathy.
This controversy has resurfaced with vigor since the publication last March in Le Figaro vitriol a tribune of a hundred doctors opposed to this practice, and demanding the termination of its partial coverage by health insurance.
Two weeks ago, the Ministry of Health approached the High Authority for Health (HAS) to assess the effectiveness of homeopathy and the "merits" of its reimbursement. The opinion of the HAS, on which the government will be based to decide, is expected by the end of February.
On Wednesday the Boiron group also published its first half results, which reflect its difficulties, particularly in France, its main market.
Net profit decreased by 13.1% to 21.6 million euros over the last six months, while operating income decreased by 13.8% to 35.38 million euros.
At issue, "the decrease in turnover and the significant rise in industrial production costs reflecting all investment and development efforts", according to the group, whose share price has fallen more than 12% since the beginning of the year.
Over the first half of the year, sales declined by 1.5% (+ 0.9% at constant exchange rates) year-on-year, totaling 280.5 million euros, according to figures already disclosed. in July.05/09/2018 19:50:45 - Paris (AFP) - © 2018 AFP
[*/quote*]
Die Nebelschwaden mit Familie etcetera, etcetera kann man ignorieren. Aber die Umsatz- und Gewinnverluste nicht!
Interessant ist die Zeiteinteilung: ein halbes Jahr! Dabei war am Anfang des Jahres die Erklärung der 124 im Figaro noch nicht draußen. Die hat erst Monate später stattgefunden und deshalb ist der Verlust am Anfang des Jahres 2018 auch noch gar kein Verlust gewesen, nehme ich an. Dafür war der danach einsetzende Verlust um so stärker und ist nur durch die noch nicht gesunkenen Monatsumsätze der ersten Monate aufgefangen worden. Jetzt, im August, wo auch noch die Universität Lille Homöopathie aus der Medizinerausbildung entfernt hat, sind die Verluste pro Monat erheblich stärker und bestimmt größer als nur 1,5%. Ich tippe auf mindestens 3%. Es könnten aber auch 5 sein. Wenn ein großer Teil des Umsatzes auf Erkältungsmittel entfällt, waren die ein Umsatzbringer im Winter. Aber jetzt nicht mehr. Das sieht gar nicht gut aus für Boiron. Es ist ein großer Schritt vorwärts für die Menschheit.
Der AFP-Artikel ist schlampig geschrieben, so daß man nicht weiß, was die meinen. Jetzt müßte man eine genaue Statistik zur Hand haben. Daran ließe sich so einiges zeigen.
